Vertex Pharmaceuticals Inc


  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • *S&P 500 pulls back after hitting intraday record. NEW YORK, June 24- U.S. stocks fell on Tuesday as early enthusiasm from economic data faded and concerns about the violence in Iraq gave investors a reason to sell and book some profits, driving the Dow to its biggest drop in over a month. On Tuesday, the Dow suffered its biggest drop since May 20.

  • Dow hit hardest as Iraq concerns overtake US data Tuesday, 24 Jun 2014 | 4:09 PM ET

    Stocks fell, with the S&P 500 turning lower after rising to another record.

  • Look for more upside in these biotech names: Pro Tuesday, 24 Jun 2014 | 2:48 PM ET

    Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.

  • NEW YORK, June 24- U.S. stocks turned lower on Tuesday after stronger-than-expected data lifted them to a fresh record earlier in the day, while the sterling tumbled after the Bank of England governor said spare capacity would need to be used up before a rate rise is needed.

  • *S&P 500 pulls back a bit after hitting intraday record. NEW YORK, June 24- U.S. stocks mostly slipped on Tuesday as earlier gains from economic data faded, but the Nasdaq advanced as a result of gains in biotech shares.

  • Stock soars on stunning results on cystic fibrosis Tuesday, 24 Jun 2014 | 12:12 PM ET
    Vertex Pharmaceuticals' headquarters in South Boston.

    A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.

  • US STOCKS-Data lift Wall St, S&P hits another record Tuesday, 24 Jun 2014 | 12:00 PM ET

    *S&P 500 hits intraday record, continues recent strength. NEW YORK, June 24- U.S. stocks rose on Tuesday, boosted by some strong data while the Nasdaq outperformed thanks to gains in technology and biotech shares. Consumer confidence hit its highest level since January 2008 in June, while new home sales jumped 18.6 percent to a six-year high in May.

  • Midday movers: DR Horton, Micron, Walgreen & More Tuesday, 24 Jun 2014 | 11:23 AM ET

    Take a look at some of Tuesday's midday movers.

  • *Consumer confidence at highest since Jan 2008. NEW YORK, June 24- U.S. stocks were little changed on Tuesday as some strong data wasn't enough to solidly lift indexes in the wake of a recent rally, though the Nasdaq index was boosted by gains in technology and biotech shares.

  • NEW YORK, June 24- U.S. stock index futures pointed to a flat open on Tuesday, suggesting investors continued to search for direction following a sharp rally that took indexes to records last week.

  • June 24- A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease.

  • This new drug combo could stun biotech this year Monday, 23 Jun 2014 | 2:36 PM ET
    Eric Olson, Vice President of the Cystic Fibrosis Franchise at Vertex Pharmaceuticals, holds a Kalydeco pill, at his office in Cambridge, Mass.

    Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.

  • It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • *Hewlett-Packard's revenue misses Wall St estimates. Among momentum names, noted for high growth and perceptions of excessive valuation, Vertex Pharmaceuticals shares shot up 6 percent to $71.18, while Alexion Pharmaceuticals rose 2.5 percent to $160.48.

  • May 1- Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.

  • May 1- Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage trial, and its shares rose 10 percent after the news.

  • After-hours buzz: Expedia, Kraft, OpenTable & more Thursday, 1 May 2014 | 4:46 PM ET

    Check out which companies are making headlines after the bell Thursday: Expedia, Kraft, OpenTable

  • A rebound is looming: Beware the dead-cat bounce Monday, 7 Apr 2014 | 6:39 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Any rebound in the market is likely to be short-lived since it needs a catalyst to sustain gains, and the start of earnings season may disappoint.

  • Wall St Week Ahead-Momentum names may see more pain Friday, 4 Apr 2014 | 9:04 PM ET

    Familiar names such as Netflix, Facebook and Tesla Motors, along with a number of biotechnology and cloud-computing stocks, have been pummeled in the last month. Facebook Inc, for example, has fallen nearly 22 percent from an intraday record reached less than a month ago.